Bevacizumab at recurrence in high-grade glioma

Andrea Salmaggi, Paola Gaviani, Andrea Botturi, Elena Lamperti, Giorgia Simonetti, Daniela Ferrari, Antonio Silvani

Research output: Contribution to journalArticle

Abstract

Bevacizumab has been introduced in the management of high-grade gliomas after preliminary studies that showed an acceptable safety and a marked increase in clinico-radiological responses in comparison with second-line chemotherapy. The objective is to synthetically review the present use of bevacizumab-alone or in combination-in the context of recurrent high-grade glioma and highlight the future developments. The methodology of this study is to analyse and discuss relevant literature studies using bevacizumab in recurrent high-grade glioma. Bevacizumab may be used as single-agent therapy in recurrent high-grade glioma, with good clinico-radiological responses having little effect on survival. The open questions and developments include new MRI criteria for evaluation of response to anti-angiogenic agents, the identification of putative factors predicting response/failure of bevacizumab and the introduction of bevacizumab in first-line management of high-grade glioma.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - 2011

    Fingerprint

Keywords

  • Bevacizumab
  • High-grade glioma
  • Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology
  • Dermatology

Cite this